We see our role as co-explorers inspired by revolutionary ideas, partnering with outstanding scientists to redefine the way diseases are studied, diagnosed, and treated.
The convergence of biology and technology has created enormous opportunities to harness transformational science and technology to confront the most pressing challenges facing modern-day health systems and practitioners.
We believe that breakthrough scientific research drives the most transformative HealthTech innovations.
About aMoon Explorer
aMoon Explorer program aims to harness Israel’s pioneering scientific research
and do-the-impossible culture to seize these unique opportunities and bring revolutionary ideas to life quickly.
For the program’s second cohort, aMoon partnered with M-Ventures to bring our cumulative expertise, global networks, financial capabilities, and development tools to translate revolutionary ideas to practice.
We are searching for highly-disruptive, high-impact proposals for sponsored translational breakthrough academic research in three areas: longevity, infertility and genomic editing.
Projects selected for funding in this program will receive project development and strategic support, as well as 500K ILS in funding.
We believe that breakthrough scientific research drives the most transformative HealthTech innovations.
We see our role as co-explorers inspired by revolutionary ideas, partnering with outstanding scientists to redefine the way diseases are studied, diagnosed, and treated.
About aMoon Explorer
The convergence of biology and technology has created enormous opportunities to harness transformational science and technology to confront the most pressing challenges facing modern-day health systems and practitioners.
aMoon Explorer program aims to harness Israel’s pioneering scientific research
and do-the-impossible culture to seize these unique opportunities and bring revolutionary ideas to life quickly.
For the program’s second cohort, aMoon partnered with M-Ventures to bring our cumulative expertise, global networks, financial capabilities, and development tools to translate revolutionary ideas to practice.
We are searching for highly-disruptive, high-impact proposals for sponsored translational breakthrough academic research in three areas: longevity, infertility and genomic editing.
Projects selected for funding in this program will receive project development and strategic support, as well as 500K ILS in funding.
JOIN THE JOURNEY
aMoon Explorer
aMoon is a global HealthTech and Life Sciences investment fund headquarter in Israel.
As Israel’s largest HealthTech VC fund, with $1.3 billion AUM, we partner with outstanding entrepreneurs who harness groundbreaking science and technology to transform healthcare. Together with our portfolio companies, we work tirelessly to advance solutions that will help people live healthier, better lives.
aMoon Velocity is aMoon’s early-stage investment fund. Our investments target disruptive, cutting edge technologies and range from sponsored research at top academic and clinical institutions, to venture formation and seed investments.
We don’t define ourselves by vertical, need, or even geographical boundaries but by our passion for partnering with entrepreneurs and scientists developing new solutions to major healthcare challenges. aMoon Velocity can take an idea from inception through commercialization; we strive to help entrepreneurs see the whole road ahead and ensure we plan from the start for each company’s success.
M Ventures is the strategic, corporate venture capital arm of Merck.
From its headquarters in the Netherlands and offices in Germany, USA and Israel, M Ventures invests globally in transformational ideas driven by innovative entrepreneurs. Taking an active role in its portfolio companies, M Ventures teams up with management teams and co-investors to translate scientific discoveries into commercial success. M Ventures focuses on identifying and financing novel solutions to some of the most difficult challenges, through company creation and equity investments in fields that will impact the vitality and sustainability of Merck’s current and future businesses.
Since inception, M Ventures has been instrumental in the creation and progress of over 80 global companies, helping advance multiple medicines and technologies to market launch. M Ventures invests, with dual strategic and financial foci, into visionary companies that find new ways to: treat the most challenging diseases, empower scientists with cutting-edge research and development tools, develop new solutions that change the way in which information is accessed, stored, processed, and displayed and address some of the most complex challenges in sustainability and technology convergence. The fund has the mandate to invest in four focus areas: Healthcare, Life Sciences, Electronics and Frontier Tech and Sustainability, in alignment with the strategic interests of Merck’s business areas.
aMoon is a global HealthTech and Life Sciences investment fund headquarter in Israel.
As Israel’s largest HealthTech VC fund, with $1.3 billion AUM, we partner with outstanding entrepreneurs who harness groundbreaking science and technology to transform healthcare. Together with our portfolio companies, we work tirelessly to advance solutions that will help people live healthier, better lives.
aMoon Velocity is aMoon’s early-stage investment fund. Our investments target disruptive, cutting edge technologies and range from sponsored research at top academic and clinical institutions, to venture formation and seed investments.
We don’t define ourselves by vertical, need, or even geographical boundaries but by our passion for partnering with entrepreneurs and scientists developing new solutions to major healthcare challenges. aMoon Velocity can take an idea from inception through commercialization; we strive to help entrepreneurs see the whole road ahead and ensure we plan from the start for each company’s success.
M Ventures is the strategic, corporate venture capital arm of Merck.
From its headquarters in the Netherlands and offices in Germany, USA and Israel, M Ventures invests globally in transformational ideas driven by innovative entrepreneurs. Taking an active role in its portfolio companies, M Ventures teams up with management teams and co-investors to translate scientific discoveries into commercial success. M Ventures focuses on identifying and financing novel solutions to some of the most difficult challenges, through company creation and equity investments in fields that will impact the vitality and sustainability of Merck’s current and future businesses.
Since inception, M Ventures has been instrumental in the creation and progress of over 80 global companies, helping advance multiple medicines and technologies to market launch. M Ventures invests, with dual strategic and financial foci, into visionary companies that find new ways to: treat the most challenging diseases, empower scientists with cutting-edge research and development tools, develop new solutions that change the way in which information is accessed, stored, processed, and displayed and address some of the most complex challenges in sustainability and technology convergence. The fund has the mandate to invest in four focus areas: Healthcare, Life Sciences, Electronics and Frontier Tech and Sustainability, in alignment with the strategic interests of Merck’s business areas.